**Back          to Table of Contents**

----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**FORM      10-QSB**

| x | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934 |
|---|-----------------------------------------------------------------------------------------------------------------|

|   | For                the quarterly period ended July 31,                2006 |
|--------|----------------------------------------------------------------------------|

| o | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934 |
|---|------------------------------------------------------------------------------------------------------------------|

|   | For                the transition period from _______ to                _______ |
|--------|---------------------------------------------------------------------------------|

**Renhuang      Pharmaceuticals, Inc.**

**Nevada**

| **0-24512**                             | **88-1273503**                                      |
|-----------------------------------------|-----------------------------------------------------|
| (Commission                File Number) | (IRS                Employer Identification Number) |

**No.      281, Taiping Road, Taiping District,**

**Harbin,      Heilongjiang Province, 150050**

**P.      R. China**

**86-451-5762-0378      **

**86-451-57620378**

----

----

**Back        to Table of Contents**

**INDEX**

|                       |                                                                                                                                 | Page   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------|
| **PART                I**  | **FINANCIAL                INFORMATION**                                                                                             |   |
|                       |                                                                                                                                 |   |
| Item                1.     | Unaudited                Condensed Consolidated Balance                Sheets                                                        | 3      |
|                       |                                                                                                                                 |   |
|                       | Unaudited                Condensed Consolidated Statements of                Operations                                              | 4      |
|                       |                                                                                                                                 |   |
|                       | Unaudited                Condensed Consolidated Statements of Cash                Flows                                              | 5      |
|                       |                                                                                                                                 |   |
|                       | Notes                to Unaudited Condensed Consolidated Financial                Statements                                         | 6      |
|                       |                                                                                                                                 |   |
|                       | Pro                Forma Financial Statements                                                                                        | 8      |
|                       |                                                                                                                                 |   |
|                       | Pro              Forma              Balance Sheet                                                                                    | 9      |
|                       |                                                                                                                                 |   |
|                       | Pro              Forma              Income Statement                                                                                 | 10     |
|                       |                                                                                                                                 |   |
|                       | Notes              to              Pro Forma Financial Statments                                                                     | 11     |
|                       |                                                                                                                                 |   |
| Item                2.     | Management’s                Discussion and Analysis of                Operations                                               | 12     |
|                       |                                                                                                                                 |   |
| Item                3.     | Controls                and Procedures                                                                                               | 13     |
|                       |                                                                                                                                 |   |
| **PART                II** | **OTHER                INFORMATION**                                                                                                 | 14     |
|                       |                                                                                                                                 |   |
| Item                4.     | Properties                                                                                                                           | 14     |
|                       |                                                                                                                                 |   |
| Item                5.     | Related                Party Transactions                                                                                            | 14     |
|                       |                                                                                                                                 |   |
| Item                6.     | Legal                Proceedings                                                                                                     | 14     |
|                       |                                                                                                                                 |   |
| Item                7.     | Submission                of Matters to a Vote of Security                Holders                                                    | 14     |
|                       |                                                                                                                                 |   |
| Item                8.     | Merger                with Renhuang Pharmaceuticals,                Inc.                                                             | 14     |
|                       |                                                                                                                                 |   |
| Item                9.     | Change                and Disagreement with Accountants on Accounting and                Financial Disclosure                        | 15     |
|                       |                                                                                                                                 |   |
| Item                10.    | Departure                of Directors or Principal Officers; Election of                Directors; Appointment of Principal Officers | 15     |
|                       |                                                                                                                                 |   |
| Item                11.    | Correction                of 8-K Disclosure                                                                                          | 15     |
|                       |                                                                                                                                 |   |
| Item                12.    | Exhibits                                                                                                                             | 16     |
|                       |                                                                                                                                 |   |
|                       | Signatures                                                                                                                           | 17     |
|                       |                                                                                                                                 |   |
|                       | Index                to Exhibits                                                                                                     | 18     |

----

**Back            to Table of            Contents**

**PART      I - FINANCIAL INFORMATION:**

| **ITEM              1.** | **UNAUDITED                CONDENSED CONSOLIDATED FINANCIAL                STATEMENTS** |
|--------------------------|-----------------------------------------------------------------------------------------|

**RENHUANG      PHARMACEUTICALS, INC**

**CONDENSED      CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

|                                                                                              |   |                        |        |                         |   |
|---------------------------------------------------------------------------------------------------|--------|-----------------------------|-------------|------------------------------|--------|
|                                                                                              |   | **July                31,** |        | **April                30,** |   |
|                                                                                              |   | **2006**                    |        | **2006**                     |   |
| **ASSETS**                                                                                        |   |                        |        |                         |   |
| Current                assets:                                                                    |   |                        |        |                         |   |
| Cash                and cash equivalents                                                          |   | $                           | —     |                         | $      | — |   |
| Totals                                                                                            |   | $                           | —     |                         | $      | — |   |
|                                                                                              |   |                        |        |                         |   |   |   |
| **LIABILITIES                AND STOCKHOLDERS' DEFICIENCY**                                       |   |                        |             |                         |   |  |   |
| Current                liabilities:                                                               |   |                        |             |                         |   |  |   |
| Advance                from stockholders                                                          |   |                        | —     |                         |   | — |   |
| Total                liabilities                                                                  |   |                        | —     |                         |   | — |   |
|                                                                                              |   |                        |        |                         |   |   |   |
| Commitments                and contingencies                                                      |   |                        |             |                         |   |  |   |
| Stockholders'                deficiency:                                                          |   |                        |             |                         |   |  |   |
|     Preferred                stock - no par value; 2,500,000 shares           |   |                        |             |                         |   |  |   |
|      authorized;                none issued or outstanding               |   |                        | —     |                         |   | — |   |
|     Common                stock - $.001 par value; 100,000,000 shares         |   |                        |             |                         |   |  |   |
|      authorized;                13,355,181 shares issued and outstanding |   |                        | 13,355      |                         |   | 13,355 |   |
| Additional                paid-in capital                                                         |   |                        | 17,375,011  |                         |   | 17,375,011 |   |
| Deficit                accumulated during the development stage                                   |   |                        | (17,388,366 | )                            |   | (17,388,366 | ) |
| Total                stockholders' deficiency                                                     |   |                        | 0.00        |                         |   | 0.00 |   |
| Totals                                                                                            |   | $                           | —     |                         | $      | — |   |
|                                                                                              |   |                        |        |                         |   |   |   |
|                                                                                              |   |                        |        |                         |   |   |   |

----

**Back            to Table of            Contents**

**RENHUANG      PHARMACEUTICALS, INC**

**CONDENSED      CONSOLIDATED STATEMENTS OF      OPERATIONS**

|                                                              |   |                              |   |
|-------------------------------------------------------------------|--------|-----------------------------------|--------|
|                                                                   |   | Three                Months Ended |   |
|                                                              |   | July                31, 2006      |   |
| Operating                expenses:                                |   |                              |   |
|     General                and administrative |   | $                                 | 0.00   |   |
|     Totals                                    |   |                              | 0.00   |   |
|     Net                loss                   |   | $                                 | 0.00   |   |
|     Net                loss per share         |   | $                                 | 0.00   |   |
|                                                              |   |                              |   |   |
| Weighted-average                common shares                     |   |                              |        |   |
|     outstanding                - basic        |   |                              | 0.00   |   |
|                                                                   |   |                              |   |   |
|                                                                   |   |                              |   |   |

----

**Back            to Table of            Contents**

**RENHUANG      PHARMACEUTICALS, INC**

**CONDENSED      CONSOLIDATED STATEMENTS OF CASH      FLOWS**

**THREE      MONTHS ENDED JULY 31, 2006 **

|                                                                                                                                                     |   |                         |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------|--------|
|                                                                                                                                                     |   | Three                Months  |   |
|                                                                                                                                                     |   | Ended                        |   |
|                                                                                                                                                     |   | July                31, 2006 |   |
| Operating                activities:                                                                                                                     |   |                         |   |
|     Net                loss                                                                                                          |   | $                            | 0.00   |   |
|                Net                cash used in operating activities           |   |                         |   |   |
| Financing                activities:                                                                                                                     |   |                         |        |   |
|                    Net proceeds from issuance of common stock                                                                             |   |                         | 0.00   |   |
| Advances                from stockholders                                                                                                                |   |                         | 0.00   |   |
|                 Net                cash provided by financing activities |   |                         | 0.00   |   |
| Net                decrease in cash and cash equivalents                                                                                                 |   |                         | 0.00   |   |
| Cash                and cash equivalents, beginning of period                                                                                            |   |                         | 0.00   |   |
| Cash                and cash equivalents, end of period                                                                                                  |   | $                            | 0.00   |   |
|                                                                                                                                                     |   |                         |   |   |
|                                                                                                                                                     |   |                         |   |   |

----

**Back            to Table of            Contents**

**RENHUANG      PHARMACEUTICALS, INC**

**NOTES      TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL      STATEMENTS**

**NOTE      1. **
**BUSINESS      DESCRIPTION**

**NOTE      2. **
**BASIS      OF PRESENTATION:**

----

**Back            to Table of            Contents**

**NOTE      3. **
**LIQUIDITY      AND CAPITAL RESOURCES**

**NOTE      4. **
**SUMMARY      OF SIGNIFICANT ACCOUNTING POLICIES**

**Use      of estimates**

**Net      profit per share**

**Principles      of consolidation**

**NOTE      5.**
**BASIS      OF PRESENTATION: **

**NOTE      6. **
**RECENT      PRONOUNCEMENT**

**NOTE      7. **
**SUBSEQUENT      EVENT**

**Acquisition      of Harbin Renhuang Pharmaceutical Co., Ltd. (Renhuang      China)**

----

**Back            to Table of            Contents**

**PRO      FORMA **

**CONDENSED      CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      RENHUANG PHARMACEUTICALS, INC.**

**INCORPORATED      UNDER THE LAWS OF NEVADA**

**AS      OF JULY 31, 2006**

----

**Back            to Table of            Contents**

**RENHUANG      PHARMACEUTICALS, INC.**

**UNAUDITED      PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET**

**AS      OF JULY 31, 2006 (In USD)**

|                                                            |   |                              |         | **July                31, 2006** |   |                         |   |
|-----------------------------------------------------------------|--------|-----------------------------------|--------------|----------------------------------|--------|------------------------------|--------|
|                                                            |   |                              |         |                             |   |                    |   | **Pro                Forma** |   |
|                                                            |   |                              |         |                             |   | **Pro                Forma** |   |  **Consolidated** |   |
|                                                            |   | **Renhuang                China** |         | **Renhuang**                     |   | **Adjustments**              |   |  **Balance** |   |
|                                                            |   | **(a)**                           |         | **(b)**                          |   | **(c)**                      |   |   |   |
| **ASSETS**                                                 |   |                              |         |                             |   |                         |   |   |   |
| **CURRENT                ASSETS**                               |   |                              |         |                             |   |                    |   |     |   |
| Cash                and cash equivalents                        |   | $                                 | 2,227,048    |                             |   |                         |   |   |   |   | $ | 2,227,048 |   |
| Trade                receivables, net of provisions             |   |                              | 3,774,835    |                             |   |                              |   |   |  |   |   | 3,774,835 |   |
| Inventory                                                       |   |                              | 1,433,249    |                             |   |                              |   |   |  |   |   | 14,33,249 |   |
| Other                receivable, not of provisions              |   |                              | 39,011       |                             |   |                              |   |   |  |   |   | 39,011 |   |
| TOTAL                CURRENT ASSETS                             |   |                              | 7,474,143    |                             |   |               |   |   |     |   |   | 7,474,143 |   |
|                                                            |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| **PROPERTY,                PLANT AND EQUIPMENT, NET**           |   |                              | 2,614,751    |                             |   |               |   |   |    |   |   | 2,614,751 |   |
| **TOTAL                ASSETS**                                 |   | $                                 | 10,088,894   |                             | $      | —                      |   |   |       |   | $ | 10,088,894 |   |
|                                                            |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| **LIABILITIES                AND SHAREHOLDERS' EQUITY**         |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
|                                                            |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| **CURRENT                LIABILITIES**                          |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| Accounts                payable and accruals                    |   |                              |         |                             |   |                         |   |   |   |   |   |   |   |
| -                Due to related parties                         |   |                              | 414,959      |                             |   |                              |   |   |  |   |   | 414,959 |   |
| -                Due to third parties                           |   |                              | 415,191      |                             |   |                              |   |   |  |   |   | 415,191 |   |
| Other                payable                                    |   |                              |         |                             |   |                              |   |   |  |   |   |   |   |
| -                Due to related parties                         |   |                              | 131,641      |                             |   |                              |   |   |  |   |   | 131,641 |   |
| -                Due to third parties                           |   |                              | 234,027      |                             |   |                              |   |   |  |   |   | 234,027 |   |
| Dividend                payable                                 |   |                              |    |                             |   |                    |   |   |    |   |   |     |   |
| TOTAL                CURRENT LIABILITIES                        |   |                              | 1,195,868    |                             |   |                    |   |   |     |   |   | 1,195,868 |   |
| **TOTAL                LIABILITIES**                            |   |                              | 1,195,868    |                             |   | —                      |   |   |  |   |   | 1,195,868 |   |
|                                                            |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| **SHAREHOLDERS'                EQUITY**                         |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| Common                stock                                     |   |                              |         |                             |   | 13,355                       |   |   | 21,645 |   |   | 35,000 |   |
| Additional                paid-in-capital                       |   |                              | 6,271,008    |                             |   | 17,375,011                   |   |   | (21,645 | ) |   | 23,624,374 |   |
| Reserves                                                        |   |                              | 393,305      |                             |   |                              |   |   |  |   |   | 393,305 |   |
| Retained                earnings (Deficit)                      |   |                              | 2,228,713    |                             |   |                              |   |   |   |   |   | 2,228,713 |   |
| Accumulated                other comprehensive income (deficit) |   |                              |         |                             |   | (17,388,366                  | )      |   |  |   |   | (17,388,366 | ) |
| **TOTAL                SHAREHOLDERS' EQUITY**                   |   |                              | 8,893,026    |                             |   | —                      |   |   | — |   |   | 8,893,026 |   |
|                                                            |   |                              |              |                             |   |                              |   |   |  |   |   |  |   |
| **TOTAL                LIABILITIES AND SHAREHOLDERS' EQUITY**   |   | $                                 | 10,088,894   |                             | $      | —                      |   | $ | — |   | $ | 10,088,894 |   |

----

**Back          to Table of Contents**

**RENHUANG      PHARMACEUTICALS, INC.**

**UNAUDITED      PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENT**

**THREE      MONTHS ENDED JULY 31, 2006 (In USD)**

|                                                          |   |  **Three                months ended July 31, 2006** |       |
|---------------------------------------------------------------|--------|-----------------------------------------------------------|------------|
|                                                          |   |                                                      |       |   |   |   |   | **Pro                Forma** |   |
|                                                          |   | **Renhuang**                                              |       |   |   | **Pro                Forma** |   | **Consolidated** |   |
|                                                          |   | **China**                                                 |       | **Renhuang** |   | **Adjustments** |   | **Balance** |   |
|                                                          |   | **(a)**                                                   |       | **(b)** |   | **(c)** |   |   |   |
| SALES                                                         |   | $                                                         | 5,919,510  |   | $ |   |   | $ |   |   | $ | 5,919,510 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| COST                OF SALES                                  |   |                                                      | (2,402,354 | ) |   |                       |   |   |                          |   |   | (2,402,354 | ) |
| GROSS                PROFIT/(LOSS)                            |   |                                                      | 3,517,156  |   |   |  |   |   |  |   |   | 3,517,156 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| SELLING                AND DISTRIBUTION EXPENSES              |   |                                                      | (593,632   | ) |   |  |   |   |  |   |   | (593,632 | ) |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| GENERAL                AND ADMINISTRATIVE EXPENSES            |   |                                                      | (306,489   | ) |   |                       |   |   |                       |   |   | (306,489 | ) |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| INCOME                FROM OPERATIONS                         |   |                                                      | 2,617,035  |   |   | — |   |   |  |   |   | 2,617,035 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| FINANCE                COSTS                                  |   |                                                      | 4,980      |   |   |  |   |   |  |   |   | 4,980 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| INCOME                BEFORE INCOME TAXES                     |   |                                                      | 2,622,015  |   |   |  |   |   | — |   |   | 2,622,015 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| INCOME                TAXES                                   |   |                                                      | —    |   |   |     |   |   |       |   |   | — |   |
| NET                INCOME/(LOSS) ATTRIBUTABLE TO SHAREHOLDERS |   | $                                                         | 2,622,015  |   | $ | — |   | $ | — |   | $ | 2,622,015 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| NET                INCOME PER SHARE                           |   |                                                      |            |   |   |   |   |   |  |   |   | 0.0749 |   |
|                                                          |   |                                                      |            |   |   |  |   |   |  |   |   |  |   |
| SHARES                OUTSTANDING                             |   |                                                      |            |   |   |   |   |   |  |   |   | 34,999,601 |   |

----

**Back            to Table of            Contents**

| (a) | Derived                from the balance sheets of Renhuang China as of July 31,                2006 |
|-----|-----------------------------------------------------------------------------------------------------|

| (b) | Derived                from the balance sheet of Renhuang as of July, 31,                2006 |
|-----|-----------------------------------------------------------------------------------------------|

| (c) | Adjustments                relating to the share exchange agreement and the acquisition of Renhuang                China by Renhuang, including: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|  | A | -                To adjust for the exchange of Renhuang China shares for 29.75 million                newly issued shares of Renhuang |
|--|---|---------------------------------------------------------------------------------------------------------------------------------------|

|  | B | -                After the reverse merger, the Company has 34,999,601 shares common                stock                outstanding ($35,000 par value), allocated as follows: |
|--|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | 29,750,000                shares issued to former owners of Renhuang                China |
|--|--------|-------------------------------------------------------------------------------------------|

|  | · | 445,240                retained by former owners of                Renhuang |
|--|--------|-----------------------------------------------------------------------------|

|  | · | 4,804,361                shares issued to Viking Investments as investment banking                fees |
|--|--------|--------------------------------------------------------------------------------------------------------|

| (a) | Derived                from the statement of income of Renhuang China for the three months                ended                July 31, 2006 |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | Derived                from the statement of income of Renhuang for the three months ended                July                31, 2006 |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|

----

**Back            to Table of Contents**

| **ITEM                2.** | **MANAGEMENT’S                  DISCUSSION AND ANALYSIS OF ****OPERATIONS** |
|----------------------------|----------------------------------------------------------------------------------------|

**Overview**
** **

**Reverse      Merger**

----

**Back            to Table of            Contents**

**Plan      of Operation**

**Off-Balance      Sheet Arrangements**

| **ITEM              3.** | **CONTROLS                AND PROCEDURES.** |
|--------------------------|---------------------------------------------|

**Evaluation      of disclosure controls and procedures**

**Changes      in internal controls**

----

**Back            to Table of            Contents**

**PART      II - OTHER      INFORMATION**

| **ITEM              4.** | **PROPERTIES** |
|--------------------------|----------------|

| **ITEM              5.** | **RELATED                PARTY TRANSACTIONS** |
|--------------------------|-----------------------------------------------|

| **ITEM              6.** | **LEGAL                PROCEEDINGS** |
|--------------------------|--------------------------------------|

| **ITEM              7.** | **SUBMISSION                OF MATTERS TO A VOTE OF SECURITY                HOLDERS** |
|--------------------------|---------------------------------------------------------------------------------------|

| **ITEM              8.** | **HARBIN                RENHUANG PHARMACEUTICAL, CO., LTD. (RENHUANG CHINA) MERGER WITH RENHUANG                PHARMACEUTICALS, INC.** |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

----

**Back            to Table of            Contents**

| **ITEM              9.** | **CHANGE                IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL                DISCLOSURE** |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------|

| **ITEM              10.** | **DEPARTURE                OF DIRECTORS OR PRINCIPAL OFFICERS;****ELECTION                OF****DIRECTORS;                APPOINTMENT OF PRINCIPAL****OFFICERS** |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **ITEM              11.** | **CORRECTION                OF 8-K DISCLOSURE** |
|---------------------------|-------------------------------------------------|

***Error***

***Correct***

----

**Back            to Table of            Contents**

*Error *

**RENHUANG      PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET      AS AT APRIL 30, 2006” **

| **ITEM              12.** | **EXHIBITS** |
|---------------------------|--------------|

|   | Exhibit                No. | Description                                                                                         |
|--------|----------------------------|-----------------------------------------------------------------------------------------------------|
|   |                       |                                                                                                |
|   | 31.1                       | Rule                13(a) - 14(a)/15d-14(a) Certification of Chief Executive                Officer |

|   | 31.2 | Rule                13(a) - 14(a)/15d-14(a)Certification of Chief Financial                Officer |
|--------|------|----------------------------------------------------------------------------------------------------|

|   | 32.1 | Certifications                of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley                Act of 2002. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------|

|   | 32.2 | Certifications                of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley                Act of 2002. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------|

----

**Back            to Table of            Contents**

**SIGNATURES**

|                                    |                                                 |                                  |
|-----------------------------------------|------------------------------------------------------|---------------------------------------|
|                                    | RENHUANG                PHARMACEUTICALS, INC.        |
|                               |                                            |                             |
| Date:                September 18, 2006 | By:                                        | /s*/ Li                Shaoming* |
|                                    | Li                Shaoming                           |
|                                    | President                and Chief Executive Officer |

|                                         |                                   |                                           |
|----------------------------------------------|----------------------------------------|------------------------------------------------|
|                                    |                              |                                      |
| Date: September                18, 2006 | By:                          | /s/                *Edith                Kong* |
|                                         | Edith                Kong              |
|                                         | Chief                Financial Officer |

----

**Back            to Table of            Contents**

**Index      to Exhibits Filed with this Report**

| Exhibit                No. |   | Description                                                                          |
|----------------------------|--------|--------------------------------------------------------------------------------------|
|                            |   |                                                                                 |
| 1                          |   | Certification                of Chief Executive Officer, Section                1350 |

| 2 |   | Certification                of Chief Financial Officer, Section                1350 |
|---|--------|-------------------------------------------------------------------------------------------|

| 3 |   | Certification                of Chief Executive Officer, Rule 13(a) -                14(a) |
|---|--------|--------------------------------------------------------------------------------------------|

| 4 |   | Certification                of Chief Financial Officer, Rule 13(a) -                14(a) |
|---|--------|--------------------------------------------------------------------------------------------|

| 5 |   | Current                  Report Form 8 K/A filed with the Commission on March 15,                  2006 |
|---|--------|---------------------------------------------------------------------------------------------------------|

| 6 |   | Current              Report Form 10-KSB 8 K filed with the Commission on 2006-08-15,              incorporated by reference to this Current              Report |
|---|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7 |   | Current                Report Form 8 K filed with the Commission on 2006-09-11, incorporated                by                reference to this Current Report |
|---|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

----